212 results about "Healthy subjects" patented technology

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

A method and device for continuously calculating the circumference of a body segment is based on the continuous measurement of the extracellular resistance of the body segment. Also disclosed is a method and device for determining the dry weight of a dialysis patient wherein the time at which the dry weight of the patient has been achieved is identified as the time at which the patient's normalized resistivity as a function of time (ρ_N(t)) is greater than or equal to a minimum level of normalized resistivity in healthy subjects (ρ_N,H).

A system for the imaging, processing and evaluation of tissues provides prognostic and diagnostic details regarding diseased tissue. A set of quantitative measures were developed and integrated in an image-base analysis software tool designed for OCT images. The system and methods in this invention is significant because it allows assessing the optical properties and structure morphology differences between normal healthy subjects and diabetic patients with retinopathy up to ETDRS level 35 and without retinopathy.

The present invention relates generally to a diagnostic device including a prognostic assay for parameters which are indicative of a condition or event associated with the systemic vasculature. More particularly, the present invention provides an assay to detect parameters associated with a vascular disease including cardiovascular, stroke, pulmonary, renovascular, cerebrovascular, thrombotic or generalized arterial or venous condition or event including acute coronary syndrome such as but not limited to acute myocardial infarction, heart failure, atheromoma or a thrombotic condition. The identification of these parameters or more particularly a pattern of parameters enables the diagnosis of a condition or event or the determination of the risk of development of a condition or event associated to the systemic vasculature. Still more particularly, the present invention is directed to a diagnostic device comprising a set of members wherein one or more of said members has or have specific or generic binding partners in a biological sample from an animal including human subject wherein the pattern of binding of the members to the binding partners is indicative, predictive or otherwise associated with a likelihood of a condition or event within the systemic vasculature. The absence of detection of specific or generic binding partners is also of indicative or predictive value. This is particularly important in cases where patients are unable to communicate advice to a physician on their own condition, such as during surgery or for patients in a coma. It is also useful in determining the risk of a vascular disease including cardiovascular, stroke, pulmonary, renovascular, cerebrovascular, thrombotic or generalized arterial or venous conditions or events in a healthy subject or a subject entering into an exposure to risk such as surgery or chemotherapy. The present invention is useful inter alia for the identification and/or quantitation of biochemical markers of conditions or events in the systemic vasculature such as heart disease, heart disorders, infections of the heart, stroke and thrombosis as well as the determination of a risk of development of these conditions including the absence of disorders or absence of risk of the development of a disorder. The assessment of such conditions may be made in a clinical setting, as part of triage, as part of a routine testing protocol and/or as a laboratory procedure.

First, to solve the problems of the present invention, the present inventors confirmed the presence of ovarian cancer antigen-specific T cells in the peripheral blood of ovarian cancer patients by using an experimental system that detects combinations of CD4 and IL-4 or IFNγ. Next, using analogue peptides of the core protein MUC16 of the ovarian cancer-associated antibody C125, the present inventors revealed that antigen-specific CD4-positive T cells are present at an average frequency of about 4% in the peripheral mononuclear cells of patients and healthy subjects. Then, the present inventors analyzed the epitope for T cells in the core protein MUC16 of the ovarian cancer-associated antigen CA125, and determined the amino acid sequence FTLNFTITN (SEQ ID NO: 1) to be a shorter epitope. The present inventors further discovered that the analogue peptide OVCA11: GHTAPOPLLVPFTLNFTITN (SEQ ID NO: 11) is suitable for T cell activation.

The present invention concerns a new individually tailored exercise training and rehabilitation technique, referred to as “MPT: Medical Personal Trainer”. More precisely, the invention concerns an innovative method to be used in the field of physical activity and exercise training/rehabilitation programs for healthy individuals and for patients with chronic diseases. It merges together, in an interactive way, advanced notions from medicine, engineering, mathematics, artificial intelligence, in order to provide new clinical perspectives for automatic personalized health care as well as novel insights on individually-tailored management and advanced treatment, in a user-familiar setting, of healthy subjects (including elderly) and patients with chronic diseases.

Methods for detecting nonactivated basophils in a whole blood sample obtained from a normal healthy subject, methods for determining a subject's susceptibility to an allergic reaction to an allergen, where the subject has no known allergy to the allergen, methods for measuring a response to challenge with a potential allergen in a whole blood sample obtained from a subject with known allergic reactivity to allergens other than the potential allergen; and an in vitro system for reliable detection or quantification of a specific white blood cell population in a whole blood sample are described.

A rapid diagnosis method for organ specific disease state is based on obtaining an infrared absorbance spectra of a patient's blood at a frequency range from about 400 cm<-1 >to about 2000 cm<-1 >and further from about 3000 cm<-1 >to about 3100 cm<-1>. Comparing it with the predetermined normal infrared absorbance spectra of known healthy subjects for the presence or absence of predetermined features such as increase or decrease of infrared absorbance, peaks at particular frequencies allows for accurate diagnosis of a disease of an organ, including most major organs such as a heart, lungs, stomach, liver, kidneys, brain, etc.

A method of detecting the level of 5-hydroxymethylcytosines (5-hmc) in a DNA molecule of a cell having a 5-hmc prevalence lower than 0.002% of total DNA bases is provided. The method comprising:

• • (a) attaching a 5-hmc labeling agent to the DNA molecule; and
  • (b) subjecting the DNA molecule to an imaging method suitable for detecting the labeling agent, thereby detecting the level of 5-hmc in the DNA molecule. Also provided is a method of diagnosing cancer in a subject in need thereof, the method comprising:
  • (a) providing a DNA sample of a cell of the subject;
  • (b) detecting the level of 5-hmc in the DNA sample as described herein;

wherein a significant decrease in the level of 5-hmc in the DNA sample, as compared to a control DNA sample from a healthy subject is indicative that the subject has cancer.

A method of qualifying a mesenchymal stem cell (MSC) population is disclosed. The method comprises:

• • (a) ex vivo differentiating a population of mesenchymal stem cells originating from the subject towards a first lineage-specific cell, the first lineage-specific cell being associated with a brain disease;
  • (b) ex vivo differentiating a population of mesenchymal stem cells originating from a healthy subject towards the first lineage-specific cell;
  • (c) comparing an effect of the first lineage specific cell derived from the subject with an effect of the first lineage specific cell derived from the healthy subject on a second lineage specific cell associated with the brain disease, wherein a difference in the effect above or below a predetermined level is indicative of a qualification of a mesenchymal stem cell population for cell therapy of said brain disease.

An object of the present invention is. to provide an objective method for diagnosis of schizophrenia using gene expression in mononuclear cells of peripheral blood as an index, and this invention provide a method for diagnosing whether a test subject suffers from schizophrenia or not. The method according to this invention is a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said subject, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and determining alteration of the quantified level(s) of the gene(s) in said test subject is statistically significant in comparison with the quantified level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or schizophrenic patients, thereby diagnosing whether said subject is suffering from schizophrenia or not.

Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.

The present invention provides a method of using a panel of serological and genetic biomarkers to distinguish IBS subjects from healthy subjects and/or to differentiate IBS subtypes from each other. The present invention also provides a method of using one or more psychological measures of a subject in conjunction with a panel of serological and/or genetic biomarkers to further aid in diagnosing IBS or discriminating IBS subtypes from each other.

A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.

A new combined index of structure and function (CSFI) for staging and detecting glaucomatous damage is provided. An observational study including 333 glaucomatous eyes (295 with perimetric glaucoma and 38 with preperimetric glaucoma) and 330 eyes of healthy subjects is described. All eyes were tested with standard automated perimetry (SAP) and spectral domain optical coherence tomography (SDOCT) within 6 months. Estimates of the number of retinal ganglion cells (RGC) were obtained from SAP and SDOCT and a weighted averaging scheme was used to obtain a final estimate of the number of RGCs for each eye. The CSFI was calculated as the percent loss of RGCs obtained by subtracting estimated from expected RGC numbers. The performance of the CSFI for discriminating glaucoma from normal eyes and the different stages of disease was evaluated by receiver operating characteristic (ROC) curves. The mean CSFI, representing the mean estimated percent loss of RGCs, was 41% and 17% in the perimetric and pre-perimetric groups, respectively (P<0.001). They were both significantly higher than the mean CSFI in the normal group (P<Q.0( )1). The CSFI had larger ROC curve areas than isolated indexes of structure and function for detecting perimetric and preperimetric glaucoma and differentiating among early, moderate and advanced stages of visual field loss. An index combining structure and function performed better than isolated structural and functional measures for detection of perimetric and preperimetric glaucoma as well as for discriminating different stages of the disease.